Mesar

Olmesartan medoxomil, the active ingredient in Mesar, is an angiotensin II receptor blocker presented as an oral tablet for oral use. It is employed to lower elevated blood pressure in adult patients with hypertension. By selectively antagonising AT1 receptors, it reduces vasoconstriction and aldosterone‑mediated fluid retention, helping patients achieve target blood‑pressure goals.

GNH USA supplies Mesar as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies, clinics and procurement teams worldwide.

Olmesartan medoxomil belongs to the angiotensin II receptor blocker class and is used to manage high‑blood‑pressure disorders.

Hypertension: lowers systolic and diastolic blood pressure, helping to achieve guideline‑recommended targets.

Common Side Effects: - Dizziness: sensation of light‑headedness, especially after standing. - Headache: mild to moderate pressure or throbbing pain. - Fatigue: feeling unusually tired or weak. - Abdominal discomfort: mild stomach pain or nausea.

Serious or Rare Side Effects: - Angioedema: swelling of face, lips, tongue or throat that may compromise breathing. - Hyperkalemia: elevated blood potassium levels, potentially causing cardiac arrhythmia. - Acute kidney injury: sudden decline in renal function, indicated by reduced urine output or rising creatinine.

Before initiating therapy, consider the following precautions: - Blood pressure monitoring: check baseline and periodic readings to avoid hypotension. - Renal function assessment: evaluate serum creatinine and eGFR, especially in patients with existing kidney disease. - Serum potassium: monitor levels to detect hyperkalemia early. - Hypersensitivity: discontinue if signs of angioedema or severe rash appear. - Hepatic impairment: use with caution in patients with moderate to severe liver disease. - Store at below 25°C: keep in the original packaging, protect from moisture and direct sunlight.

Olmesartan medoxomil may interact with several drug classes.

Major Interactions (Avoid): - Aliskiren (in diabetic patients): combined use can increase risk of renal dysfunction and hyperkalemia. - Potassium‑sparing diuretics (e.g., spironolactone): may cause dangerous elevations in serum potassium. - ACE inhibitors (e.g., enalapril): concurrent use raises the likelihood of angioedema and hyperkalemia. - NSAIDs (e.g., ibuprofen): can blunt antihypertensive effect and impair renal function.

Moderate Interactions (Monitor Closely): - Thiazide diuretics: may enhance blood‑pressure‑lowering effect, requiring dose adjustment. - Lithium: olmesartan can increase lithium concentrations, risking toxicity. - Other antihypertensives (e.g., beta‑blockers): additive hypotensive effect may necessitate closer monitoring.